MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Kura Oncology Inc

Suletud

SektorTervishoid

6.54 2.99

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.23

Max

6.54

Põhinäitajad

By Trading Economics

Sissetulek

35M

-19M

Müük

54M

54M

Aktsiakasum

-0.22

Kasumimarginaal

-35.664

Töötajad

192

EBITDA

43M

-17M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+311.44% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-43M

570M

Eelmine avamishind

3.55

Eelmine sulgemishind

6.54

Uudiste sentiment

By Acuity

40%

60%

146 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Kura Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2025, 23:55 UTC

Kuumad aktsiad

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2. apr 2025, 22:50 UTC

Suurimad hinnamuutused turgudel

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2. apr 2025, 21:08 UTC

Tulu

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2. apr 2025, 21:00 UTC

Tulu

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2. apr 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2. apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2. apr 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2. apr 2025, 23:44 UTC

Peamised uudised

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2. apr 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. apr 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. apr 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2. apr 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2. apr 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2. apr 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2. apr 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2. apr 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. apr 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2. apr 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. apr 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2. apr 2025, 22:43 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2. apr 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2. apr 2025, 21:48 UTC

Peamised uudised

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2. apr 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2. apr 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. apr 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. apr 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2. apr 2025, 21:04 UTC

Peamised uudised

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2. apr 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2. apr 2025, 20:53 UTC

Tulu

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2. apr 2025, 20:52 UTC

Tulu

Kaiser Aluminum Changes Inventory Acctg Methodology

Võrdlus sarnastega

Hinnamuutus

Kura Oncology Inc Prognoos

Hinnasiht

By TipRanks

311.44% tõus

12 kuu keskmine prognoos

Keskmine 26.25 USD  311.44%

Kõrge 40 USD

Madal 10 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Kura Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

12

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.27 / 7.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

146 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.